Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 51 - 100 out of 128,877

Document Document Title
WO/2018/081825A1
Optionally substituted benzoimidazol-1,2-yl amides, such as compounds of Formula 1 or Formula 2, can be used to treat disorders associated with a Kv7 potassium channel activator. Compositions, medicaments, and dosage forms related to the...  
WO/2018/079734A1
A medicinal composition which is in the form of granules, a powder or a preparation for syrup comprising memantine or a pharmaceutically acceptable salt thereof and an enteric polymer, said composition being easy to ingest even for aged ...  
WO/2018/080916A1
Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof, Also provided herein are pharmaceutical compositions comprising compounds of Formula (I) and methods of using compounds o...  
WO/2018/079695A1
An inhibitor for cognitive function decline or an improver for learning ability is provided. The inhibitor for cognitive function decline or the improver for learning ability contains, as an active ingredient, a liver hydrolysate having ...  
WO/2018/076782A1
The present invention provides a crystalline form of dextral oxiracetam. The crystalline form has a diffraction peak when a diffraction angle, 2θ, is 17.12±0.2°, 18.88±0.2°,19.24±0.2°, 21.18±0.2°, or 24.88±0.2°. The crystallin...  
WO/2018/078038A1
The present invention provides combination treatments comprising administration of compounds that are PDE1 enzyme inhibitors and other compounds useful in the treatment of psychiatric and/or cognitive disorders such as for example Attent...  
WO/2018/079631A1
Provided is a preventive agent which is for a growing child's anxiety, attributable to stress in infancy, and which is to be taken by an infant who has stress in infancy. Provided is a preventive agent for a growing child's anxiety, attr...  
WO/2018/081294A1
Disclosed embodiments concern novel interleukin receptor associated kinases (IRAK) inhibitors of formula 1 and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The di...  
WO/2018/076107A1
In one aspect, there is provided a method of treating, prophylaxis, or amelioration of a neurological disease by administering to a subject in need thereof minocycline, or a functional derivative thereof, and hydroxychloroquine, or a fun...  
WO/2018/078010A1
The present invention relates to polysubstituted quinic acid derivatives (abbreviated to "PSQs") of general formula (IA): in which R represents a linear or branched, cyclic or branched cyclic, saturated or unsaturated C2-Cp alkyl group, ...  
WO/2018/079862A1
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R1, R2, R3 and n are as defined in the specification, a process for their preparation, pharmaceutical compositions containing t...  
WO/2018/078042A1
The present invention provides combination treatments comprising administration of compounds that are PDE1 enzyme inhibitors and other compounds useful in the treatment of neurodegenerative disorders such as for example Alzheimer's Disea...  
WO/2018/081590A1
The present disclosure provides proteins, nucleic acids, vectors, and host molecules useful for the production of compounds of interest, and methods for their use.  
WO/2018/080573A1
Provided herein are methods for identifying genetic networks and methods of treating neurodegenerative disorders associated with α-synuclein dysfunction.  
WO/2018/078631A1
Methods for predicting antidepressant treatment response for a subject in need thereof, for predicting resistance to antidepressant treatment, and for generating a predictor of response to antidepressant treatment, are provided.  
WO/2018/081384A1
The present disclosure relates to compounds of formula I which inhibit NaV1.7, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions. (I)  
WO/2018/078112A1
A method is provided for treating multiple sclerosis and/or cognitive impairment in patients with multiple sclerosis by providing a GLP-1 receptor agonist. Kits are also provided, which comprise a GLP-1 receptor agonist and one or more f...  
WO/2018/077157A1
Disclosed are polymorphic forms of sodium benzoate with a X-ray diffraction pattern comprising characteristic peaks at a reflection angle 2 θ of approximately 5.9, 30.2, and 31.2 degrees; or a X-ray diffraction pattern comprising charac...  
WO/2018/079493A1
The purpose of the present invention is to provide a new pharmaceutical composition for prevention or treatment of hydrocephalus, and a diagnosis kit that does not place a heavy burden on a patient. Further, the purpose of the present in...  
WO/2018/076108A1
ABSTRACT In one aspect, there is provided a method of treating, prophylaxis, or amelioration of a neurological disease by administering to a subject in need thereof one or more compounds described herein. In a specific example, the neuro...  
WO/2018/079759A1
The present invention provides a compound having a TrkA inhibitory activity or a pharmaceutically acceptable salt of the compound. The present invention relates to: a compound represented by formula (I) or a pharmaceutically acceptable s...  
WO/2018/081821A1
Disclosed are compositions of matter, treatment methods, and combination therapies for addressing panic attacks in patients suffering from Panic Disorder (PD). In one embodiment the invention provides the use of Noble Gas containing mixt...  
WO/2018/081378A1
The present disclosure is directed to pyridazinone derivatives of generic formula that modulate, e.g., address underlying defects in cellular processing of CFTR activity.  
WO/2018/076784A1
A crystalline form of (R)-4-hydroxy-2-oxo-1-pyrrolidineacetamide is disclosed. The crystalline form has a diffraction peak when a diffraction angle, 2θ, is 16.66±0.2°, 17.54±0.2°, 21±0.2°, 22.16±0.2°, or 30.96±0.2°. The crysta...  
WO/2018/075698A1
Compounds are provided according to Formula (A): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, R3, R4, R5, R6, and RG are as defined herein. Compounds of the present invention are...  
WO/2018/072742A1
The present invention relates to a crystalline form of a free base of an imidazo isoindole derivative and a preparation method therefor. Specifically, the present invention relates to the A, B, C, D, E, and F crystal forms of the compoun...  
WO/2018/075981A2
A method, system and apparatus for administering various medicaments including those for treating pain and substance dependency are disclosed. The apparatus is a unit for heat activation of a morphine opiate liquid concentrate mixed with...  
WO/2018/075865A1
In one embodiment, the present application discloses methods of treating diseases and disorders with sulfasalazine, an ABCG2 inhibitor and pharmaceutical formulations of sulfasalazine where the bioavailability of the sulfasalazine is inc...  
WO/2018/075901A1
The present disclosure provides a method for delivering a neuroprotective polypeptide to at least a portion of a central nervous system (CNS) of a subject. The method includes administering to the systemic blood circulation of the subjec...  
WO/2018/071967A1
The present invention relates to the use of scaffolds to enhance the viability of cells implanted in the integumentary system such that the cell may release an agent. The scaffold is capable of protecting the cell, as well as allowing fo...  
WO/2018/075450A1
The present invention describes compositions and method for improving outcomes after injury to the central nervous system wherein complement signaling is activated. In one aspect, the method comprises administering to a subject a therape...  
WO/2018/073963A1
The present invention addresses the problem of providing a means for improving the profile of mood state of a subject. This problem is solved by a profile of mood state improving agent that comprises bacteria belonging to Lactobacillus p...  
WO/2018/072015A1
Disclosed is a device and method for treating a neurodegenerative disease or condition associated with neuroinflammation induced by a leukotriene. The device is a film unit dosage form having a film layer and a safe and effective amount ...  
WO/2018/072689A1
The present invention provides a stachydrine derivative, a preparation method therefor, and applications thereof in the preparation of drugs for treating cardiovascular and cerebrovascular diseases. The stachydrine derivative is a compon...  
WO/2018/073251A1
The present invention provides compounds according to formula (I) below that are PDE1 enzyme inhibitors and their use as medicaments, in particular for the treatment of neurodegenerative disorders and psychiatric disorders. The present i...  
WO/2018/072348A1
Disclosed is the use of a bone morphogenetic protein-9 in the preparation of a pharmaceutical composition for treating and/or preventing diseases associated with the degeneration of the cholinergic system. The cholinergic system is a cen...  
WO/2018/072697A1
Disclosed are an oxadiazole ring-containing compound, a preparation method therefor, and an intermediate, a composite, and an application thereof. The oxadiazole ring-containing compound having the formula in the figure below, and a phar...  
WO/2018/074463A1
[Problem] To elucidate a mechanism associated with neuropathy in methylmalonic acidemia, and to develop a novel therapeutic agent or the like for neuropathy in organic acidemia on the basis of this finding. [Solution] The present invento...  
WO/2018/073414A1
The invention concerns the use of Lepista flaccida intended for treating a disease caused by a nonsense mutation of a gene resulting in the premature introduction of a UGA and/or UAA stop codon. It also concerns a Lepista flaccida extrac...  
WO/2018/072673A1
Disclosed in the present are a drug for adjusting the activity of platelets, a reagent kit, a screening method therefor, and applications thereof in preventing or treating thrombotic thrombocytopenic purpura and other diseases related su...  
WO/2018/075481A1
The present invention provides compositions and methods for treating diseases or disorders using a therapeutically effective amount of a NMDA receptor antagonist and a therapeutically effective amount of a μ-opioid receptor antagonist. ...  
WO/2018/072614A1
Provided in the present invention is a quinolinyl-substituted carboxylic acid compound as shown in formula (I) or a pharmaceutically acceptable salt thereof, and also disclosed are a preparation method and the use of the compound and a p...  
WO/2018/075699A1
Compounds are provided according to Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R2, R3, R4, R5, and and R6 are as defined herein. Compounds of the present invention are con...  
WO/2018/075339A1
The present invention provides a method of treating a cognitive or neurodegenerative disease, comprising administering to a patient in need of such treatment an effective amount of a compound of the formula (I):or a pharmaceutically acce...  
WO/2018/074565A1
Provided is a novel compound having a P2X7 receptor inhibitory action, and a pharmaceutical composition having a P2X7 receptor inhibitory action. a compound represented by Formula (I), or a pharmaceutically acceptable salt or the like th...  
WO/2018/071532A1
The present disclosure is in the field of pharmaceutical compositions suitable for the treatment of diseases in mammals. The disclosure provides novel compositions comprising non-pathogenic fecal microbes for treating chronic fatigue syn...  
WO/2018/069843A1
The present invention relates to an oxazine derivative BACE-1 inhibitor and pharmaceutical compositions comprising such oxazine derivative for use in the treatment or prevention of cerebral amyloid angiopathy and, in particular, wherein ...  
WO/2018/068566A1
An application of albiflorin or a pharmaceutically-acceptable salt thereof in production of products for regulating and improving the balance of the human intestinal flora. Albiflorin or a pharmaceutically-acceptable salt thereof, as a r...  
WO/2018/069732A1
This invention relates to compounds that are agonists of the muscarinic M1 receptor or M1 and M4 receptors and which are useful in the treatment of muscarinic M1 or M1/M4 receptor mediated diseases. Also provided are pharmaceutical compo...  
WO/2018/071741A1
The invention provides sulfoxyalkyl organonitro and related compounds, compositions containing such compounds, and methods for using such compounds and compositions to treat medical disorders, such as a neurodegenerative disorder, autoim...  

Matches 51 - 100 out of 128,877